College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board

Graadt van Roggenweg 500
3531 AH Utrecht
The Netherlands

DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Pharmasin 250 000 IU/g Oral Granules for pigs

Created: July 2021

MODULE 1

PRODUCT SUMMARY

EU Procedure number	NL/V/0129/002/DC
Name, strength and pharmaceutical form	Pharmasin 250 000 IUg Oral Granules for pigs
Applicant	Huvepharma NV, Uitbreidingstraat 80, 2600 Antwerp, Belgium
Active substance(s)	Tylosin activity (as tylosin phosphate) : 250 000 IU per g.
ATC Vetcode	QJ01FA90
Target species	Pigs
Indication for use	Pigs: Treatment and prevention of clinical signs of porcine proliferative enteritis (porcine intestinal adenomatosis, proliferative hemorrhagic enteropathy, ileitis) associated with *Lawsonia intracellularis* when the disease has been diagnosed at the group level.

Pharmasin 250 000 IUg Oral Granules for pigs	NL/V/0129/002/DC
Huvepharma NV	DCP
	Publicly available assessment report

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Veterinary Medicines Agencies website (http://www.HMA.eu).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Decentralised procedure application in accordance with Article 13 (1) of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	3rd December 2009
Date product first authorised in the Reference Member State (MRP only)	Not applicable
Concerned Member States for original procedure	Belgium, Czech Republic, Denmark, Germany, Italy, and Poland

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.
It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC
The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.
The efficacy of the product was demonstrated according to the claims made in the SPC.
The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Qualitative and quantitative particulars

The product contains Ttosin (as tylosin phosphate): 250 000 UI per g (quantitative) and the excipients (qualitative) wheat meal , dipotassium phosphate and pregelatinised starch (potato)

The container/closure system contains 5 kg LDPE/paper-paper-paper with sutured crimp and 1 kg PE/Alu/PET bag

The choice of the formulation is justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

The product is manufactured in accordance with the European Pharmacopoeia and relevant European guidelines.

C. Control of Starting Materials

The active substance is tylosin (as tylosin phosphate), an established active substance described in the European Veterinary Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

Scientific data and/or certificates of suitability issued by the EDQM have been provided and compliance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products has been satisfactorily demonstrated.

D. Control on intermediate products

Not applicable.

E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

F. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

G. Other Information

Shelf life of the veterinary medicinal product as packaged for sale: 24 months.
Shelf-life after first opening the immediate packaging: 3 months

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of pharmacological and toxicological tests are not required.

The pharmacological and toxicological aspects of this product is/are identical to the reference product.

Warning statements and precautions as listed in the product literature are based on those of the reference product and supplemented with additional statements, based on increased knowledge and the current state of science. This information is considered adequate to ensure safety of the product to the animals, users, consumers and the environment.

III.A Safety Testing

Pharmacological Studies

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of pharmacological and toxicological tests are not required.

Toxicological Studies

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of pharmacological and toxicological tests are not required.

User Safety

Warning statements and precautions as listed in the product literature are based on those of the reference product and supplemented with additional statements, based on increased knowledge and the current state of science. This information is considered adequate to ensure safety of the product to the animals, users, consumers and the environment.

Environmental Risk Assessment

The applicants states that the current application is an extension of the original licensed product Pharmasin 20 mg/g Oral Granules for pigs, namely addition of a strength to the original product, approved as generic under art. 13 of Directive 2001/82/EC as amended.

No changes to the nature of the ingredients used, the indications, the target species, the dosing schedule or the administration route is claimed.
Furthermore the applicant has demonstrated the bioequivalence of Pharmasin 250 mg/g Oral Granules with Pharmasin 20 mg/g Oral Granules, Tylan 25% and Tylan 2%. Based on bioequivalence and the identical use pattern of both concentrations, the applicant claims that no further environmental data will be needed.

In view of the above it can be accepted that this additional strength will not influence the possible impact on the environment and the absence of additional data is justified.

III.B Residues documentation

Residue Studies

As this is a generic application according to Article 13, and bioequivalence with the reference product has been demonstrated, results of residue depletion studies are not required.

Residue Studies

No residue depletion studies were conducted because this application is an extension of the original licensed product Pharmasin 20 mg/g Oral Granules for pigs and since the product covered by this extension has been proven to be bioequivalent to the licensed product, no safety and residue studies have been performed.

Withdrawal Periods

Based on the above the following withdrawal period is justified:

Pigs (meat) :zero days

IV. CLINICAL ASSESSMENT (EFFICACY)

Since this application is an extension of the original licensed product Pharmasin 20 mg/g Oral Granules and since the product covered by this extension has been proven to be bioequivalent to the licensed product, clinical studies have not been performed. The following indications as approved for the licensed product Pharmasin 20 mg/g Oral Granules are applicable:

Pigs: Treatment and prevention of clinical signs of porcine proliferative enteritis (porcine intestinal adenomatosis, proliferative hemorrhagic enteropathy, ileitis) associated with *Lawsonia intracellularis* when the disease has been diagnosed at the group level.

V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Heads of Vetrinary Medicines Agencies website (www.HMA.eu).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

Summary of change	**Section updated**	**Approval date**
Change of the withdrawal period from 1 to 0 days extrapolation of the conclusions of a zero days withdrawal period. (NL/V/0129/002/II/001)	Module 3 III.B	26th August 2012
New DDPS and new QPPV (NL/V/xxxx/WS/001)	NA	23rd November 2012
Renewal- NL as RMS (NL/V/0129/002/R/001)	NA	20th November 2014
Change in the test procedure of the finished product. (NL/V/xxxx/WS/012)	NA	25th May 2018
Change in the test procedure of the active substance. (NL/V/XXXX/WS/019)	NA	3rd August 2019
C.I.3. a) Implementation of wording agreed by the competent authority (NL/V/xxxx/WS/029)	Module 1 & 2	25th April 2020
Change in test procedure of active substance (NL/V/XXXX/WS/031)	NA	20th august 2020